NUVB NUVATION BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, NUVATION BIO INC reported revenue of $31.7M (up 555.6% from a year earlier), net income of −$62.8M and diluted EPS of −$0.18; over the last four quarters revenue was $170M and net income −$150M; for the fiscal year ended December 2025 revenue was $62.9M, up 699.0% on the year before.
NUVB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $62.9M, gross profit n/a, operating income −$213M, net income −$205M (margin -325.3%), EPS −$0.60
- Fiscal year ended Dec 2024: revenue $7.87M, gross profit $795K, operating income −$593M, net income −$568M (margin -7213.8%), EPS −$2.11
- Fiscal year ended Dec 2023: revenue $0, gross profit $0, operating income −$99.8M, net income −$75.8M (margin n/a), EPS −$0.35
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$120M, net income −$104M (margin n/a), EPS −$0.48
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$93.3M, net income −$86.8M (margin n/a), EPS −$0.44
NUVB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $31.7M (up 555.6% year over year), net income −$62.8M, EPS −$0.18
- Quarter ended Mar 31, 2026: revenue $83.2M (up 2598.7% year over year), net income $5.40M, EPS $0.01
- Quarter ended Dec 31, 2025 (from the annual report): revenue $41.9M (up 633.1% year over year), net income −$36.6M, EPS −$0.11
- Quarter ended Sep 30, 2025: revenue $13.1M (up 1704.7% year over year), net income −$55.8M, EPS −$0.16
- Quarter ended Jun 30, 2025: revenue $4.83M (up 236.8% year over year), net income −$59.0M, EPS −$0.17
- Quarter ended Mar 31, 2025: revenue $3.08M, net income −$53.2M, EPS −$0.16
- Quarter ended Dec 31, 2024 (from the annual report): revenue $5.71M, net income −$49.4M, EPS $0.00
- Quarter ended Sep 30, 2024: revenue $727K, net income −$41.2M, EPS −$0.15
- Quarter ended Jun 30, 2024: revenue $1.44M, net income −$462M, EPS −$1.89
- Quarter ended Mar 31, 2024: revenue $0, net income −$14.8M, EPS −$0.07
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$13.8M, EPS −$0.07
- Quarter ended Sep 30, 2023: revenue $0, net income −$19.6M, EPS −$0.09
- Quarter ended Jun 30, 2023: revenue $0, net income −$20.6M, EPS −$0.09
- Quarter ended Mar 31, 2023: revenue n/a, net income −$21.7M, EPS −$0.10
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$20.8M, EPS −$0.10
- Quarter ended Sep 30, 2022: revenue n/a, net income −$27.2M, EPS −$0.12
- Quarter ended Jun 30, 2022: revenue n/a, net income −$34.9M, EPS −$0.16
- Quarter ended Mar 31, 2022: revenue n/a, net income −$21.3M, EPS −$0.10
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$25.1M, EPS −$0.12
- Quarter ended Sep 30, 2021: revenue n/a, net income −$22.0M, EPS −$0.11
NUVB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$173M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$130M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$68.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$96.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$68.2M, share buybacks n/a
NUVB balance sheet
- Jun 30, 2026: cash $259M, total assets $745M, total liabilities $491M, shareholders' equity $254M
- Mar 31, 2026: cash $125M, total assets $610M, total liabilities $291M, shareholders' equity $320M
- Dec 31, 2025: cash $164M, total assets $595M, total liabilities $289M, shareholders' equity $306M
- Sep 30, 2025: cash $98.9M, total assets $602M, total liabilities $276M, shareholders' equity $326M
- Jun 30, 2025: cash $248M, total assets $647M, total liabilities $274M, shareholders' equity $373M
- Mar 31, 2025: cash $48.0M, total assets $492M, total liabilities $73.0M, shareholders' equity $419M
- Dec 31, 2024: cash $35.7M, total assets $541M, total liabilities $76.8M, shareholders' equity $464M
- Sep 30, 2024: cash $30.0M, total assets $572M, total liabilities $68.9M, shareholders' equity $503M
What is NUVB's revenue?
NUVATION BIO INC reported $170M of revenue over its last four quarters, through June 30, 2026.
Is NUVB profitable?
No. NUVATION BIO INC lost $150M over the last four quarters.
What is NUVB's EPS?
Diluted earnings per share over the last four quarters were −$0.44; −$0.18 in the latest quarter.